All articles by GlobalData
GlobalData
@globaldataplc
BioCardia submits Japan application for CardiAMP to treat ischemic HFrEF
If approved by the PMDA, CardiAMP would be a minimally invasive stem cell therapy option for patients with ischemic systolic HF.
Artificial intelligence advances cancer diagnostics in the next decade
GlobalData predicts that more IVD manufacturers will adopt AI tech into their devices to improve diagnostic and treatment predictions.
Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo
Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) versus Yervoy alone in patients with anti-programmed death protein-1 (anti-PD-1)-refractory advanced melanoma did not meet its co-primary endpoint of objective response rate (ORR).
Chinese checkpoint inhibitors are poised to change global IO markets
The Chinese Government’s significant R&D investments in recent years has resulted in the successful commercialisation and launch of several domestically developed therapeutic agents.
Turning point: November marked by promising Covid-19 vaccine development data
With the global devastation of Covid-19 continuing into 2021, the month of November marks a turning point in the pandemic timeline. A number of sponsors have released Phase III vaccine trial results in this month with all vaccines displaying good efficacy and generally well-tolerated safety profiles
Jardiance fails to deliver in EMPERIAL trials for heart failure
The trial failure places doubt on the success of Jardiance in further trials for HF-REF and HF-PEF and may impact the uptake of the drug.
Astellas expands into gene therapy with $3bn acquisition of Audentes
The acquisition of Audentes will allow Astellas to expand into a fifth primary focus area: genetic regulation.
Evaluating NICE guidelines in regards to cannabis-based medicinal products targeting pain
Campaigners argue the new regulations are not extensive enough where the recommendation of cannabis-based medicine for pain is concerned.
IDWeek 2019: Long-acting antiretroviral therapy shows promise for HIV patients with low adherence
HIV infections can be well controlled with antiretroviral therapy to a degree where the viral load is not detectable anymore.